| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 778 8 |
| Ultima descărcare din IBN: 2024-01-05 17:02 |
| Căutarea după subiecte similare conform CZU |
| 616.5-002-525-2-07 (1) |
| Piele. Tegumente în general. Dermatologie clinică. Tulburări cutanate (210) |
 SM ISO690:2012GOLUBCIUC, Victor, ŢIRULIC, Ecaterina, EVSTRATOVA, Ludmila, COCA, Ruslan. Lupusul eritematos sistemic: dificultăţi de diagnostic. In: Sănătate Publică, Economie şi Management în Medicină , 2017, nr. 3(73), pp. 208-210. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 3(73) / 2017 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| CZU: 616.5-002-525-2-07 | ||||||
| Pag. 208-210 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Systemic lupus erythematosus (SLE) is considered to have a global occurrence of 2-8 new cases per 100.000 people, with a global prevalence at 30-50 cases per 100.000 people. Recent estimates however suggest these numbers have tripled in the last thirty years. Ages 15 to 45 are being primarily affected; male to female ratio is 1:8-10 with a predilection for younger females. A lingering disease with remissions and flares, SLE reaches a sustained remission in 25% of cases; up to 50% develop irreversible organ damage. The multiorgan spread marks the disease severity; multiple systems may be involved at once: pulmonary, cardiovascular, GI, ocular and renal involvement, skin, muscle and joint and psycho-neurologic affects. SLE is a systemic disease often difficult to diagnose and treat. Atypical presentations – with progressive evolution resistant to aggressive treatment strategies and associated to multiple comorbidities – only begin to describe the challenges when approaching the clinical aspects of a SLE. Multiple medical professionals have to contribute to the management of a patient with SLE due to the systemic nature of the disease. We hope the described case reflects the above-mentioned diagnostic challenges and peculiarities when dealing with this disease. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-55741</cfResPublId> <cfResPublDate>2017-07-01</cfResPublDate> <cfVol>73</cfVol> <cfIssue>3</cfIssue> <cfStartPage>208</cfStartPage> <cfISSN>1729-8687</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/55741</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Lupusul eritematos sistemic: dificultăţi de diagnostic</cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'><p><em>Systemic lupus erythematosus (SLE) is considered to have a global occurrence of 2-8 new cases per 100.000 people, with a global prevalence at 30-50 cases per 100.000 people. Recent estimates however suggest these numbers have tripled in the last thirty years. Ages 15 to 45 are being primarily affected; male to female ratio is 1:8-10 with a predilection for younger females. A lingering disease with remissions and flares, SLE reaches a sustained remission in 25% of cases; up to 50% develop irreversible organ damage. The multiorgan spread marks the disease severity; multiple systems may be involved at once: pulmonary, cardiovascular, GI, ocular and renal involvement, skin, muscle and joint and psycho-neurologic affects. SLE is a systemic disease often difficult to diagnose and treat. Atypical presentations – with progressive evolution resistant to aggressive treatment strategies and associated to multiple comorbidities – only begin to describe the challenges when approaching the clinical aspects of a SLE. Multiple medical professionals have to contribute to the management of a patient with SLE due to the systemic nature of the disease. We hope the described case reflects the above-mentioned diagnostic challenges and peculiarities when dealing with this disease.</em></p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-54314</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-40060</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-54387</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-54388</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-54314</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-54314-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Golubciuc</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-40060</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-40060-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Ţirulic</cfFamilyNames> <cfFirstNames>Ecaterina</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-54387</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-54387-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Evstratova</cfFamilyNames> <cfFirstNames>Ludmila</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-54388</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-54388-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-07-01T24:00:00</cfStartDate> <cfFamilyNames>Coca</cfFamilyNames> <cfFirstNames>Ruslan</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>
|
|
|
